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Chapter 1: A Background of Tuberculosis 
Abstract 
 Tuberculosis is an ancient disease caused by one of the most virulent and fatal biological 
agents; Mycobacterium tuberculosis (M. tuberculosis).  Active pulmonary tuberculosis (TB) 
infection, which was nearly eradicated a generation ago, started to reemerge in a concerning 
manner in the late 1980’s and the dawn of the 21st century.    Different categories of TB (latent, 
active, and extrapulmonary) infections were explored in depth in this study.  Each of the three 
types exhibits specific pathophysiology, characteristic clinical features, and epidemiological 
patterns. The synergistic role of co-infection with human immunodeficiency virus (HIV) in 
activating TB infections was addressed in the context of diagnosis and treatment.  Additionally, 
the complex correlation between a rather lengthy, diverse, and oftentimes inadequate case-




The clinical course of tuberculosis (TB) usually comes in two steps: latent TB infection 
(LTBI) and active disease.  LTBI is an inactive form of tuberculosis caused by the pathogen M. 
tuberculosis.  TB is a stepwise process as 1 out of every 10 individuals that have LTBI go on to 
develop an active TB disease (World Health Organization, 2014). 
 Initially, an individual has LTBI when she/he is infected with M. tuberculosis but has no 
symptoms of the disease.  About one-third of the world’s population is already infected with 
LTBI (World Health Organization, 2014). However, during its latent stage, LTBI is not 
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contagious and cannot be transmitted from one person to another (Virginia Department of 
Health, 2011).  Many of those infected do not seek medical care for LTBI because they have no 
symptoms and may not know about their illness.  Nevertheless, according to the National Centers 
for Disease Control and Prevention (CDC), there are six main categories for individuals who 
should be tested for TB:  individuals who have spent time around active TB cases; individuals 
who have human immunodeficiency virus (HIV) or are otherwise immunocompromised; those 
that have TB symptoms such as  fever, coughing, and night sweats; individuals living in Latin 
America, Africa, Asia, and Eastern Europe; Americans that live in high risk neighborhoods such 
as homeless shelters or nursing homes; and individuals who use illegal substances (CDC, 
Testing, 2014).   The Mantoux tuberculin skin test (TST) and the QuantiFERON-TB Gold-In 
Tube (QTF-GIT) blood assay are the two main laboratory tests used to screen for TB infections.  
Both tests have inherent limitations including high rates of false positive for the skin test and the 
need for phlebotomy to perform QTF-GIT.  However, QTF-GIT is considered more reliable for 
detecting TB (Cağlayan et al, 2011). Izoniazid is the antibiotic most widely used to treat patients 
diagnosed with LTBI; however, unlike most antibiotic therapy, LTBI management requires three 
to nine months of treatment (CDC, Treatment, 2014). 
According to the World Health Organization (WHO), 10 percent of all LTBI patients 
who did not receive adequate treatment will advance to develop active TB (WHO, 2014). The 
progression to active TB disease is usually enhanced and promoted after an LTBI patient 
becomes immunocompromised due to contracting an immunocompromising disease such as 
HIV, developing type II Diabetes Mellitus, or as a side effect of receiving long-term treatment 
with immunosuppressing medications. Immunocompromised patients are at a greater risk for 
developing active TB because they have fewer white blood cells to fight the bacteria (CDC, 
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Figure 1.    Illustrates the airborne mode of transmission for M. tuberculosis (Rook et al, 2005)  
Basic TB Facts, 2014).  Once the disease is active, TB infection usually attacks the lung tissues 
causing characteristic TB lesions.  Active TB patients usually seek medical care because of 
fatigue, chest pain, and possible blood in their sputum. (CDC, Diagnosis, 2014)   Although active 
TB is frequently contained within the lungs, it can spread to other parts of the body.  The 
progression of active TB disease is called extrapulmonary TB.  M. tuberculosis can attack the 
meninges, lymphatic system, and bones; the spread of TB infection to other organs makes it 
more serious and more lethal (Houston et al, 2014).   
 
Patients diagnosed with active pulmonary TB disease or an extrapulmonary TB, must be 
treated with a combination of four antibiotic drugs:  Isoniazid, Rifampicin, Ethambutol and 
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Pyrazinamiden.  Similar to LTBI, active TB disease management requires at least six months of 




As illustrated in Figure 1, TB is an airborne disease and susceptible individuals can 
contract the bacteria and become infected with M. tuberculosis through inhaling infected small 
droplets that contain this pathogen. Such droplets are suspended in air after an individual who is 
already infected with active TB coughs or sneezes.  Once inhaled, these droplets are deposited 
into the distal alveoli and become ingested by alveolar macrophages, neutrophils, or dendritic 
cells (Philips et al, 2012). Although the macrophages engulf the M. tuberculosis with the 
intention of destroying it, the bacteria survive and travel to the interstitium of lungs where it can 
establish a base for infection (Orme et al, 2014).  This mechanism of survival is not very well 
understood, but the general consensus is that M. tuberculosis takes residence in the endosomes 
and cytosol of the macrophage and survives the leukocytes acidic environment.  Then after that it 
causes the macrophage to become necrotic and lyse (rupture), which allows the bacteria to 
spread to the interstitium and activate the disease (Behar et al, 2010). The bacteria can stay at the 
site of the interstitial spaces of the lungs or spread to different parts of the body via the lymphatic 
system.  
Compared to the majority of people that are exposed to M. tuberculosis, only a small 
minority actually develop active TB. This is due to the inhalation of greater concentrations of the 
bacteria instead of the minuscule amounts of the pathogen that most people breathe (Orme et al, 
2014). After contracting the infection, M. tuberculosis multiply in the lungs without activating a 
massive inflammatory response.  However, once the cell-mediated immunity develops, the 
Azzam 5 
 
bacteria are eventually engulfed by monocytes and macrophages.  These white blood cells 
become more destructive to the mycobacteria, causing the formation of the characteristic 
granulomas of the disease.  A granuloma is an aggregation of lymphatic and necrotic cells that 
have killed most of the bacteria and stopped the infection.  However, some of the individuals 
who previously were able to arrest the progress could develop an immunosuppressive event such 
as that associated with  acquired immune deficiency syndrome (AIDS) or a prolonged treatment 
with corticosteroids that would  inhibit the cell-mediated immunity.  Subsequently, the formerly 
sealed TB can flare up and lead to active TB (Crowley, 2009). 
 Active TB disease can exhibit several forms; the most common and most understood of 
those is active pulmonary TB infection, which is associated with granulomas in the upper lobes 
of the lungs.  However, the two most dangerous kinds of tuberculosis are miliary TB and 
tuberculosis pneumonia.  The former is when the mycobacterium spreads to blood vessels, which 
in turn causes the disease to distribute large amounts of M. tuberculosis throughout the body. 
The latter mainly occurs among immunosuppressed individuals when the disease attacks larger 
portions or another lobe of the lung causing unusually severe symptoms.   
Either through miliary TB or lymphatic TB, extrapulmonary TB disseminates when the 
infection spreads to body organs and tissues other than the lungs.  Secondary TB infections can 
be spread to the bones, kidneys, uterus, and other reproductive organs. Such extrapulmonary 







 Tuberculosis infections are characterized in two parts: asymptomatic LTBI and 
symptomatic active TB disease.  There are many important symptoms that can prompt an 
individual with active TB to seek medical care.  The classic and most obvious symptoms of 
active TB disease include night sweats, fatigue, chest pain, chronic cough, and blood-stained 
sputum.  However, since TB is not a stationary disease, there is a wide variety of symptoms that 
M. tuberculosis can cause. 
 Pulmonary TB is usually categorized by its six cardinal symptoms: chronic cough, fever, 
weight loss, fatigue, chest pain/discomfort, sweating, and blood in sputum.  On the other hand, 
these main, nonspecific symptoms can commonly be attributed to other less serious illnesses 
such as the common cold and influenza infection (Craig et al, 2014).  More advanced signs of 
active pulmonary TB may include scarring of the lungs, hydrothorax (fluids in the lungs), and 
possible hemorrhaging from a Rasmussen’s aneurism (pulmonary artery aneurism), which may 
lead to massive hemoptysis (Crowley, 2009). 
 Extrapulmonary TB can exhibit a wide variety of signs and symptoms that are directly 
related to its infection site.  The main extrapulmonary TB infections may include the central 
nervous system (CNS), the genitourinary tracts, the bones and joints, and the lymphatic system. 
Most of the CNS tuberculosis infections are associated with severe signs and symptoms of 
bacterial meningitis.  Tuberculous meningitis (TB meningitis) may rapidly exacerbate from an 
initial stage with no clear symptoms to the specific signs of meningitis including stiff neck, 
lethargy, and cranial nerve palsies.  The final stage of TB meningitis is characterized with severe 
clinical manifestations of encephalitis such as clouding of consciousness, coma, paralysis and 
death (Jaypee, 2006).    
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Genitourinary TB is mainly characterized with progressive and diurnal enuresis (loss of 
urinary control), dysuria (painful urination), chronic scrotal dull pain and induration due to 
epididymitis in males, and lower abdominal pain with amenorrhea in females (2006).  
Osteoarticular TB is mainly categorized with arthralgia (joint pain) and atrophy around 
the joints known as tubercular arthritis.  It may also cause bone deformities causing exaggerated 
kyphosis and oftentimes lordosis which may result in paralysis due to a persistent compression of 
the spinal cord (2006).   
A relatively rare form of extrapulmonary TB infection is the peripheral tuberculous 
lymphadenitis which includes adenopathy (swollen lymph nodes) and a large painless cervical 
mass (neck mass) known as the cold abscess (2006). 
 




The epidemiology of tuberculosis (TB) is characterized by several crucial variables such 
as age, sex, race/ethnicity, geographic location, and environmental and socioeconomic risk 
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factors.  Figure 2 illustrates the trends of active TB infections by age and sex. Children less than 
4 years of age are at higher risk for developing a primary TB infection than their older siblings.  
Additionally, in such young infants, TB infections have a much higher chance of disseminating 
to different systems and organs in the body.   
Among all age groups, children age 5 to 19 years of both genders have the lowest 
chances of contracting a TB infection.  However, from that point on, the risk of developing TB 
infections starts to increase reflecting significant sex-related differences.  Adult males age 20 and 
older exhibit higher incidence rate and subsequently are at higher risk to contract TB compared 
to adult females in the same age group.  (Donald et al, 2010). 
 
 Figure 3. 2011 - New cases of TB by Country of Residence (Feleke et al, 2012) 
Risk factors for contracting TB may include race/ethnicity and the geographic location or 
country of residence. Figure 3 illustrates the high frequency of TB infections observed in 
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developing countries around the world.  Populations of African countries especially sub-Saharan 
Africa, and residents of developing countries in Asia are most likely to become infected with TB.  
Additionally, the incidence and distribution of active TB around the world seems to mirror that 
of the HIV infection. African countries have the highest rates of HIV which synergizes the 
infectivity of M. tuberculosis and increases the spread of disease around the continent.  After one 
year of acquiring HIV, the risk of developing an active TB infection increases by more than 
100%.  High rates of the HIV infection in Africa, mediocre health care systems, and large 
population densities that live in poverty provide optimistic conditions for the continuous spread 
of TB among African and Asian countries (Feleke et al, 2012). 
 
Environmental and Socioeconomic Factors 
TB infections are associated with poverty, pollution, malnutrition, and overcrowding.  
Such environmental injustices and other socioeconomic risk factors are the main reasons that 
developing countries in the sub-Saharan Africa and East Asia have the highest rates of TB cases. 
HIV and several other infectious and parasitic debilitating diseases that are kept under control in 
North America and West Europe contribute heavily to these alarming rates of the active TB 
disease in Africa.  Tobacco use and alcohol abuse are additional behavioral risk factors that may 
increase an individual’s risk to contract TB infections.  
Although the treatment for nations in Africa and East Asia are lackluster, a focus on 
reducing such risk factors could lead to a decline in TB infections, and a decrease in the 
mortality rate. Currently TB infections kill more adults worldwide than all other infectious 
diseases combined (WHO, 2014). Scarce public health and healthcare resources, inadequate 
housing, and a severe lack of funding for education, training, and environmental hygiene must be 
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Figure 4.  Result of a tuberculin skin test is measured by its induration not it erythema 
(WebMD, 2013) 




 The diagnosis of TB is a multi-step process, and it should start with screening for LTBI.  
The two main tests to determine if an individual has LTBI are the tuberculin skin test (TST) and 
the QuantiFERON-Gold blood test.  Up until the late 2000’s, the TST, also known as the 





This skin test is performed by injecting 5 units of purified protein derivative (PPD) intradermally 
into a patients forearm.  Then it should be read 2-3 days later and be measured by the length of 
its induration (hardness) not its erythema (redness).  Figure 4 illustrates how the test is read by a 
medical professional. The key issue with the skin test is it may bring about false positive results 
especially if the patient has a mycobacterium other than M. tuberculosis or if the patient had a 
history of receiving the Bacillus Calmette-Guerin (BCG) vaccine.  The skin test might also 
reveal false negative results, which is when a patient actually has TB but the TST does not 




Figure 5. X-Ray of patient with progressive pulmonary tuberculosis (Medline Plus, 2012) 
immunocompromised or malnourished patient, since they cannot mount a strong immune 
response to the PPDs.  Because HIV attacks the body defenses and destroys the white blood 
cells, the TST may show up as a false negative even if the patient does in fact have TB (Knechel, 
2009). 
 The next major test to detect LTBI is the QuantiFERON-Gold blood assay for the cell-
mediated reactivity to the mycobacterium by measuring the amount of interferon gamma (IFNγ) 
that is released from leukocytes.  The QuantiFERON-Gold blood test provides results in 24 
hours, and in addition to LTBI, it can also detect active tuberculosis.  Additionally, the CDC now 






While the QuantiFERON-Gold blood test can detect active TB, radiology imaging as represented 
in Figure 5 can pinpoints the exact anatomic location and the extent of TB infection in the lungs.  
Figure 5 illustrates a patient with advanced pulmonary TB. The light areas or opacities are 
mainly located in the upper lobe. These opacities are due to granuloma formation, which contain 




Figure 6. (A) coronal plane CT scan and (B) coronal plane FDG PET/CT scan of the same patient 
with progressive pulmonary tuberculosis, (C) transverse plane CT scan and (D) transverse plane 
FDG PET/CT (Harkirat et al, 2008) 
pulmonary diseases may very look similar to TB (Medline Plus, 2012). Other tests that are used 
to diagnose active TB are sputum smears and sputum cultures, CT scans, and PET scans.  
Sputum smears are generally the first laboratory test to detect active TB because M. tuberculosis 
is present only in the sputum of a patient with active TB.  Sputum smear requires sputum to be 
spread on a slide then stained and treated with alcohol.  If any mycobacteria are present, it will 
remain stained.  Also, much like the other tests for TB, the sputum smear can read false positives 
by staining another species of mycobacterium that are not M. tuberculosis (Knechel, 2009). 
Sputum culture and antibiogram can be a lengthy process and are used to further characterize the 
biological agent and test its in-vitro sensitivity for TB medications. 
 
The newest technique for identifying TB comes in the form of CT and PET Scans.  These 
scans play an important role because they can detect TB even in patients who had inconclusive 
X-Ray imaging.  The left side of Figure 6 shows a CT scan of a patient with pulmonary 
tuberculosis, while, the right shows a fludeoxyglucose (FDG) PET/CT image of that same 
patient.  The PET/CT scan illustrates the difference between a cancerous lung and one that is 
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infected with TB. By injecting a patient with FDG, a TB lesion stains about 10 times brighter 
than a cancerous legion. Furthermore, the FDG PET/CT scan can also detect extrapulmonary TB 




 After a diagnosis of TB, the treatment depends on the type of infection. LTBI can be 
treated with one of three antibiotics (Isoniazid, Rifapentine, and Rifampin).  Such treatment 
should be initiated only after the possibility of active TB disease has been excluded.  Treatment 
regimens for LTBI may vary in duration ranging from 3 months to 9 month.  While patients with 
LTBI do not have any symptoms and may not like to undergo an extensive treatment plan, it is 
important to understand that treatment at such an early stage is essential to prevent the 
development of active TB and stop any further spread of the infection.  
Active TB can be treated with 4 antibiotics: Isoniazid (INH), rifampin (RIF), ethambutol 
(EMB), and pyrazinamide (PZA).  Table 1 shows the 3 main regimens for treatment of active 
TB. Each treatment regimen has an initial phase and a continuation phase. The most common 
regimen requires a total of 26 weeks.  Moreover, it is essential for TB patients to comply with the 
prescribed daily medication in order to prevent antibiotic resistance, which is an ever growing 
problem in the realm of medicine (CDC, Treatment, 2014).  The emergence of drug resistant 
biological agent can be associated with the overuse and misuse of antibiotics. Multiple drug 
resistant tuberculosis (MDR-TB) occurs when M. tuberculosis becomes resistant to the two main 
antibiotic drugs that treat TB, which are Isoniazid and Rifampin.   Drug resistance can also be 
the result of interrupted, erratic, and meager treatment plans.  Since TB treatment guidelines are 
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not universally respected, certain strains of extremely drug-resistant TB (XDR-TB) have 
emerged making it exceedingly difficult to treat this reemerging disease (TB Alliance, 2014). 
Multi drug resistance acquired by dangerous biological agents such as M. tuberculosis is causing 
serious complications and is increasing the cost of treatment as well as the lethality due to TB.   
Table 1. Basic TB Disease Treatment Regimens (CDC, Treatment, 2014) 
Preferred Regimen Alternative Regimen Alternative Regimen 
Initial Phase 
Daily INH, RIF, PZA, and 
EMB* for 56 doses (8 weeks) 
Initial Phase 
Daily INH, RIF, PZA, and 
EMB* for 14 doses (2 weeks), 
then twice weekly for 12 doses 
(6 weeks) 
Initial Phase 
Thrice-weekly INH, RIF, PZA, 




Daily INH and RIF for  
126 doses (18 weeks) 
or 
Twice-weekly INH and RIF for 
36 doses (18 weeks) 
Continuation Phase 
 
Twice-weekly INH and RIF for  
36 doses (18 weeks) 
Continuation Phase 
 
Thrice-weekly INH and RIF for 
54 doses (18 weeks) 
 
Conclusion  
M. tuberculosis is a protean and extremely infectious pathogen that is difficult to treat 
and easily spread.  TB can reside in the alveoli of the lungs and lie dormant in its latent stage. 
Once active, it has the ability to spread through cough and small droplets in the air until it finds a 
new susceptible host.  Diagnosing TB is a difficult task because the symptoms, laboratory tests, 
and radiography results are rather vague and oftentimes nonspecific.  Additionally, testing for 
TB reveals a fairly high rate of false positives and false negatives results.  Furthermore, once TB 
is diagnosed, the patient must be given a comprehensive and rather rigid treatment regime that 
requires at least 6 months of multiple antibiotics which may have unpleasant, adverse effects. 
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Inefficient treatment regimens allow the mycobacterium to mutate and acquire extra resistance to 
medications.   If treatment plans are not properly followed, stronger and more virulent strains of 
TB may develop rendering the serious illness even more challenging to manage and treat.   
The already heavy medical, epidemiological, financial, and societal burden of TB in 
developing countries with poor medical care and dense populations continues to exacerbate.  
Effective methods of prevention, early detection, screening, contact tracing, and control of the 
spread of M. tuberculosis have been utilized in countries like the United States.  Nevertheless, it 
is necessary to utilize similar approaches in developing countries in order to control and 
ultimately eliminate this pathogen before it becomes even more resistant.  
Since much of the pathophysiology of TB is the subject of complex ongoing research and 
studies, there is promise that a better understanding of its mechanisms will result in more 
efficient community-based interventions, treatment therapies, and case management that will 
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Chapter 2: Immunopathogenesis of M. tuberculosis due to inhibition of macrophage 
plasma membrane repair and mitochondrial degradation 
Abstract 
 The key component of a virulent strand of Mycobacterium tuberculosis (Mtb) is related to 
its ability to induce macrophage necrosis in place of cell mediated apoptosis.  Macrophage (Mφ) 
necrosis depends mainly on the Mtb infection leading to plasma membrane micro-disruptions 
(micro-lesions) and interference with the plasma membrane repair mechanism.  Membrane repair 
depends on the translocation of vesicles derived from lysosomes and the Golgi apparatus which 
is dependent on prostaglandin E2 (PGE2).  Once a cell membrane is restored, it undergoes 
negative feedback, and lipid mediators release lipoxin A4 (LXA4) to block PGE2 and stop cell 
membrane repair. The virulence of Mtb is reliant on its ability to induce LXA4 production and 
block PGE2 biosynthesis. Without proper repair mechanisms, the Mφ undergoes cell necrosis, 
and Mtb effectively evades a host innate defenses.  Additionally, Mtb has been shown to 
negatively affect the mitochondrial outer membrane (MOM) and the mitochondrial 
transmembrane potential (Δψm).  Some virulent strands of Mtb have illustrated a formidable 
ability to disrupt the MOM and cause substantial loss of Δψm, which leads to the destruction of 
the mitochondria and cell necrosis.  Mtb’s combination of inhibiting plasma membrane repair 
and degrading the mitochondria effectively induces Mφ necrosis leading to Mφ lysis, which 
releases the Mtb into the surrounding tissue; thus, infecting more cells and repeating the cycle. 
 
Introduction 
 M. tuberculosis (Mtb) is known to be one of the most infectious and destructive 
facultative bacterial parasites.  It kills 1.5 million people each year and effects 33 percent of the 
Azzam 21 
 
world’s population.  Humans are easily infected by Mtb because it is an airborne pathogen 
(WHO, 2014).  After inhalation of the Mtb, the body’s innate immunity uses pulmonary 
macrophages (Mφ) to phagocytize the foreign invaders in an effort to destroy the pathogen.  
When the pathogen is avirulent or attenuated, the Mφ is freely allowed to undergo plasma 
membrane repair and eventual apoptosis to rid itself of the mycobacterium (Chen et al, 2006).   
 Plasma membrane repair is enhanced by the release of PGE2, which protects against 
necrosis and regulates the Ca2+ dependent sensors: synaptotagmin 7 (Syt-7) for lysosome and 
neuronal calcium sensor 1 (NCS-1) for the Golgi apparatus.  Both Syt-7 and NCS-1 are involved 
in vesicle transport that brings modified proteins to the cell membrane to fix old or injured 
membrane component. Although membrane repair is crucial for a cells survival, it is especially 
important for Mφ that are infected with Mtb because this pathogenic agent  is equipped with a 
specialized protein secretion system known as ESX 1, which is  thought to poke holes in the Mφ 
membrane. While a Mφ has the ability to reseal lesions of its cell membrane, virulent strains of 
Mtb have the ability to induce the production of LXA4 which shuts down PGE2 synthesis 
(Divangahi et al, 2009).   
 In addition to negatively impacting plasma membrane repair, Mtb also affects the Mφ 
mitochondria.  Virulent strains of Mtb have been shown to disrupt the mitochondrial outer 
membrane (MOM).  This disruption of the MOM leads to a substantial loss of mitochondrial 
transmembrane potential (Δψm), which causes mitochondrial degradation and eventual cell 
necrosis (Chen, 2006).   
It is important to emphasize that cell apoptosis defends the body against Mtb, while cell 





Fluorescence Activated Cell Sorting (FACS) analysis measured the amount of the 
expressed protein and the cells which expressed such protein. FACS analysis was used to test for 
the presence of proteins that facilitate the repair of the plasma membrane and the Δψm in Mφ. In 
order to ensure valid and reliable test results, FACS analysis used cells of the H37Rv and H37Ra 
that are stained with FDX, LAMP-1, and Mannosidase II (Mannos II) in vitro, and it deployed a 
control staining uninfected cells with FDX (Divangahi et al, 2009).  In the case of the Δψm, the 
Mφ was stained with 3, 3′-dihexyloxycarbocyanine iodide (DiOC6), which determined if the 
mitochondria changed in permeability (Chen et al, 2006).   
 
Immunoblot (Western Blot) analysis with siRNA transfection. Transfection provides an 
important tool in molecular and cellular biology studies. Through the process of transfection, 
genes can be manipulated and silenced allowing for the analysis of gene function, the 
determination of disease pathways, and the identification of potential drug targets. This research 
method demonstrated the effects of the silenced gene with stained murine antibodies that detect 
Syt-7 and NCS-1 by latching on to the molecule.  The final image is resolved on an SDS-PAGE. 
As a control, the expression of β-actin is measured with and without the siRNA transfection on 
the SDS-PAGE gel (Divangahi et al, 2009). 
 
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) - was used 
to magnify the western blot analysis by using lung tissue Mφ cultures and transcribing those into 
cDNA.  The cDNA was then denatured under high temperatures (95oC) and amplified with Max3000p 
Stragenen cyclerboth β-actin, the Syt-7, and NCS-1 (Divangahi et al, 2009) 
 
Cell Death Detection Enzyme-linked Immunosorbent Assay Plus (ELISAPlus) - The 
Cell Death Detection ELISAPLUS photometric enzyme immunoassay was  used to determine 
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whether the death of a Mφ was due to apoptosis or necrosis by analyzing the histone-associated 
DNA fragments after induced cell death (Divangahi et al, 2009) 
. 
Magnetic Activated Cell Sorting System (MACS) Column Purification - The MACS 
method allowed cells to be separated by identifying cells that get attached to magnetic 
nanoparticles coated with murine cell antibodies.  After running these cells through a column, 
cells that were coated with murine antigens would ultimately attach to the column, while the 
other cells would flow through.  This method can purify and support the Western blot analysis 
results (Divangahi et al, 2009). 
 
Confocal Fluorescence Microscopy – This method used rhodamine-2, a Ca2+-sensitive 
fluorescent dye, and MitoTracker Green, to label the mitochondria.  In order to create a confocal 
image, cultured cells with red and green dyes were excited with light at wavelengths (λ) of 488 











Figure 1.  (A) FACS analysis showing the amount of FDX+ cells from uninfected, 
H37Rv, or H37Ra infected cells. (B and C) FACS analysis of LAMP-1 and MFI in 
H37Ra and H37Rv cells (Divangahi et al, 2009). 
 
Results 
Figure 1a highlights the effects of the virulent strand (H37Rv) and the attenuated strand 
(H37Ra) on a cells plasma membrane by measuring the percent of FDX, which can only cross a 
membrane if there are lesions. As illustrated in this top figure, the uninfected cells (control) do 
not show any increase in the amount of FDX in the cell over the 48 hour time span.   
Whereas, both the Mtb strains of H37Rv and H37Ra show an increase in the percent of FDX 
throughout the 48 hours.  As expected, the virulent strand H37Rv exhibits a significantly higher 
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percent of FDX in its cell than that of the attenuated strand H37Ra; confirming that H37Rv is 
more destructive than H37Ra to the plasma membrane (Divangahi et al, 2009).   
Figure 1b and 1c illustrate the ability of the plasma membrane to repair itself after being 
infected with the two strains.  To test membrane repair, cells were stained with either LAMP-1 or 
Mannos II, and translocation to the cell membrane was measured.  LAMP-1 was used as a 
specific marker for lysosomal membrane repair, while Mannos II as a specific marker for Golgi 
membrane repair.  In both cases, H37Ra shows a greater translocation of lysosomal and Golgi 
content to the cell membrane proposing that virulent Mtb inhibits membrane repair to a far 
greater extent than attenuated Mtb (2009).  
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Figure 2. (A) Immunoblot analysis of Ca2+ sensors Syt-1 and NCS-1 after siRNA transfection 
(NT = Not Targeted, T = Targeted) (B) Translocation of LAMP-1 and Mannose II with Syt-7 
gene silenced and H37Ra infection Present (+) or  Not present ( ) (C) Translocation of 
Mannose II with NCS-1 gene silenced  and H37Ra infection (D) Translocation of LAMP-1, 




Figure 2a illustrates the ability to silence genes using siRNA transfection by 
demonstrating that when the gene to Syt-7 is silenced there is little Syt-7 in the cell, and the same 
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rules apply for NCS-1.  Figures 2b and 2c apply gene silencing to show siRNA targeting Syp-7, 
which decreases LAMP-1 translocation, and siRNA targeting CNS-1, which decreases Mannos 
II translocation to the plasma membrane.  Figure 2d clearly demonstrates the extent to which a 
virulent strain of Mtb affects a Mφ membrane.  At the LAMP-1 section, the graph shows that 
when H37Rv is present without the PGE2 inserted; LAMP-1’s ability to translocate to cell 
membrane is hindered.  Additionally, the Syt-7 section shows that its translocation is hindered 
with H37Rv present without PGE2.  Lastly, the Mannos II region is of value because it shows no 
signs of inhibition even with H37Rv.  This suggests that only the lysosomal membrane repair 
with the use of Syt-7 Ca2+ receptors is inhibited by virulent Mtb (Divangahi et al, 2009). 
 
Figure 3.  (A) Relates the Necrosis and Apoptosis of a Mφ based off multiplicities of 
infection (MOI) of Alox5-/-, WT, and Ptges-/- as well as if Ptges-/- is infected with H37Ra 
(top) or H37Rv (bottom) (B) Shows the number of Colony Forming Units (CFU) of the 




Figure 3a illustrates the process virulent strands deploy in order to survive against the 
body’s innate immune defenses.  It shows how H37Ra strains induce apoptosis and H37Rv 
strains induce necrosis.  It demonstrates the effect of a normal, wild type strain (WT), and the 
effects of the attenuated and virulent strains.  To demonstrate this process, the Ptges-/- gene was 
infected with either H37Ra or H37Rv strains revealing  that the more infection sites there are in a 
Mφ the more likely the cell will either undergo apoptosis, for H37Ra, or necrosis, for H37Rv’s.  
Since the ALOX-/- silences the biosynthesis of LXA4, ALOX-/- precipitated the least amount of 
colony forming unit, as illustrated in Figure 3b, suggesting that LXA4 is crucial for an Mtb’s -
ability to form colonies, which will eventually disperse into other cells (Divangahi et al, 2009). 
The above information addressed the process of plasma membrane repair and focused on 
the mechanism Mtb uses to inhibit the repair process. The next sections will outline the process 






To test for the change in the mitochondrial inner membrane potential (Δψm), DiOC6 was 
used as a marker in order to determine if the membrane exchanged ions. In Figure 4a, both 
H37Rv and H37Ra showed a depletion of DiOC6 with the control showing no significant change 
in DiOC6.  This depletion illustrates the dissipation of Δψm, which disrupts the mitochondria’s 
respiratory (electron transport) chain in metabolism.  H37Rv has about double the amount of 
Figure 4. (A) Compares H37Ra with H37Rv’s ability to deplete DiOC6 in Mφ (B)  MOI 
ability to deplete DiOC6 (C) Correlates DiOC6 with cytochrome c depletion (D) Control 
showing how much H37Ra is phagocytized compared to H37Rv (Chen et al, 2006).  
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DiOC6 depleted compared to H37Ra.  Figure 4b shows DiOC6 depletion based on the number of 
MOIs.  The more infection sites there are the greater the dissipation of the Δψm by H37Rv 
compared to H37Ra.  Figure 4c’s data relates the depletion of DiOC6 with the depletion of 
cytochrome c.  Depletion of cytochrome c is a marker for Mφ apoptosis.  Figure 4d shows that 
Mφ phagocytizes similar amounts of H37Rv and H37Ra strains (Chen et al, 2006). 
 
Figure 5 demonstrates that an Mtb infection leads to an influx of Ca2+ in the 
mitochondria.  This image reveals an increase in the concentration of Ca2+ at 6 hours suggesting 
a possible mechanism of Δψm dissipation.  To illustrate the effects of virulent Mtb, TG which 
increases Ca2+ ability to enter the mitochondria was added leading to a greater concentration in 
Figure 5.  Confocal image with the green dye labeling the mitochondria and red dye 
labeling Ca2+ ions of H37Ra Mφ.  Thapsigargin (TG) and Ruthenium Red (RR) 
effects on Ca2+ entering the mitochondria are shown (Chen et al, 2006). 
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the mitochondria. Furthermore, RR which abrogates Ca2+ uptake into the mitochondria was 
added as well (Chen et al, 2006).   
 
Discussion  
These experiments demonstrated that Mtb interacts with a cell causing cell necrosis in 
two different ways: inhibiting the plasma membrane repair process and degrading the 
mitochondria.   However, the severity of this dangerous infection is directly related to two 
factors.  The first is the virulence of the strain inhaled demonstrated with H37Rv, which induced 
stronger tendencies to cause Mφ necrosis than H37Ra, which more frequently induced apoptosis.  
The second factor is the concentration (dose) of the Mtb inhaled and the extent of exposure, 
which is illustrated by the correlation of MOI and necrosis.  The more infection sites there are in 
a Mφ, the more likely that cell will undergo necrosis (Divangahi et al, 2009). 
 
The first mechanism that Mtb goes through to stimulate Mφ necrosis is by disrupting the 
Mφ plasma membrane repair machinery, especially when a virulent strain of Mtb is engulfed into 
a Mφ by phagocytosis.  Once inside, the mycobacterium uses it ESX-1 protein secretion system 





Figure 6.  Morphology of Mφ infected with H37Ra and H37Rv. Uninfected Mφ 
acts as a control.  H37Ra induces apoptosis which is shown by an intact cell 





As a result of these micro lesions in the membrane, the Mφ secretes PGE2 stimulating 
lysosomes to release membrane vesicles aimed to repair the damage.  It is unclear how PGE2 
facilitates the membrane repair. However, it is well established that a virulent strain of Mtb 
inhibits the synthesis of PGE2 by activating the Mφ synthesis of LXA4.  Although the exact 
process used by Mtb to activate LXA4 synthesis in Mφ is not fully understood, it could be a topic 
for future research.  Nevertheless, LXA4 inhibits PGE2 by down regulating cyclooxygenase-2 
(COX2) mRNA accumulation.  Once PGE2 is shut down, lysosomes can no longer aid in plasma 
membrane repair.  Without the Mφ ability to repair itself, the Mφ degrades and necrosis ensues.  
While lysosomes are directly influenced by PGE2 activation, the Golgi apparatus’ membrane 
repair mechanism is not dependent on PGE2 stimulation suggesting that Mφ may have additional 
mechanisms to repair its cell membrane (Divangahi et al, 2009).   
 The experimental research also revealed that Mtb causes mitochondrial degradation and 
necrosis. H37Rv’s ability to shuttle Ca2+   into the mitochondria was demonstrated through the 
depletion of DiOC6 in a Mφ causing the dissipation of Δψm on the inner mitochondrial 
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membrane.  Once the gradient between the intermembrane space and the mitochondrial matrix is 
broken, the proton gradient that fuels the respiratory (electron transport) chain will soon get 
destroyed (Chen et al, 2006).  The Mφ loses its ATP making machine and the uncoupling of the 
respiratory chain lead to hyperproduction of superoxide anions, disruption of mitochondrial 
biogenesis, and the release of soluble intermembrane proteins. This negative cascade leads to a 
bioenergetic catastrophe that culminates in the disruption of the plasma membrane eventually 
causing necrosis.  However, mitochondrial degradation also leads to the release of specific 
proteins such as cytochrome c and other apoptosis-inducing factors, which may cause a Mφ to 
undergo apoptosis.  What determines the fate of the cell is the relative rate between bioenergetic 
catastrophes and apoptosis-inducing factor activation (Kroemer et al, 1998).  
Although inhibiting membrane repair and the degradation of mitochondria are two 
separate processes, it is possible that both have a synergistic negative effect of causing 
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Chapter 3: Case Study 
 
Patient Intro 
Name: Raul Meza 




Why he came into the ER complaint:   
 
“I woke up to have congestion and a deep cough, which I have had almost every morning for 
about 2 months. However, this time I coughed a lot of blood.   Also, my muscles and joints have felt very 




History of Present Illness 
 
 Raul has had a chronic cough for over 2 months and has recently started seeing small amounts of 
blood in his sputum.  He feels chest congestion and chest pain throughout the day but mostly when 
waking up in the morning.    Additionally, he frequently has night sweats, and he feels fatigue throughout 
the day without any strenuous activities.  He says he has had little to no appetite most days, which has led 
to a 20lb weight loss over 2 months.  
 
Past Medical History 
 
 Raul has a history of hypertension and type II diabetes.  He says he is on a healthy diet and 
exercises regularly to control his diabetes and hypertension.  He is on Vasotec to control his blood 











Hep A: 06/09/1995, 07/15/1995 
Hep B: 06/09/1995, 07/15/1995,  08/27/1995 
Yellow Fever:  11/19/1979 
BCG: none 
 





 He was born in Guadalupe, Mexico and migrated to the United States in 2008.  Currently, he 
owns his lawn care business as a gardener/handyman. He does not smoke, and denies using illicit drugs or 
abusing alcohol. He is sexually active with his girlfriend.   
 
Family History  
 
 Both parents are alive; his mother, Lucia, was a nurse, and his father, Fernando, was a middle 
school teacher in Mexico.  Neither of his parents is a smoker.  His mother’s side of the family has no 
history of diabetes, hypertension, heart disease, liver disease, or kidney disease, but his grandmother (on 
his mother’s side) developed breast cancer around 50 years of age.  His dad’s side has a history of 
diabetes and hypertension, but nothing too dramatic.  His father has type II diabetes but watches his diet 
and has mild hypertension.   
 
Review of Systems (ROS) 
 
Constitutional Symptoms: unexplained weight loss, night sweats, fatigue, dizziness, nausea, malaise, 
fever, and increased urination 
 
Eyes:  Blurred vision and headaches 
 
Cardiovascular: Chest pain and shortness of breath while at work 
 
Respiratory: Coughing especially in the morning and hemoptysis  
 







Vital signs recorded by the nurse before the physical examination: 
 
Height: 5’8”   Weight: 195 lbs    BP: 123/84 mmHg    Temp: 98.6 oF      HR: 75 bpm    
 
Respiration Rate: 25 breathes/min      O2 saturation: 81%  
 
General:   Raul is an overweight individual but still fit.  Appears agitated and nervous. 
 




Head:  Unremarkable, no tenderness 
 
Eyes: PERRLA, OS, 20/30 OD on the Snellen Chart,  
 
Ears: Light reflex and tympanic membranes are grey and intact 
 
Nose: No nasal discharge or mucosal swelling  
 




Neck:  Thyroid has normal size, lymph nodes normal and no bruits sounds of the carotid arteries 
 
Chest/Lungs: Rales (Crackles) auscultation heard in the upper lobes of the lungs during inspiration. Deep 
breaths are not labored 
 
Heart: 1/5 systolic murmur.  RRR.   S1 and S2 heard, no rub or gallop. 
 
Abdomen: Soft, no pain during palpitation, non-distended.  No organomegally. Normal bowel sounds 
 
Musculoskeletal: Slight edema of feet, but muscle tone appears normal.  No skeletal deformities 
 




Test Reference Value Result 
CBC 
RBC Count 4.2-5.9 x 106/ µl 4.1 x 106 /µl 
Hemoglobin 14-17 g/dL 14 g/dL 
Hematocrit 41-51% 40.5% 
MCV 80-100 fL 99.4 fL 
MCH 28-32 pg 32.1 pg 
MCHC 32-36 g/dL 32.2 g/dL 
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White Cell Count 4,000-10,000 /µl 12,500 / µl 
Neutrophil Count (Absolute) 1,800-7,700 /µl 4930/ / µl 
Neutrophil Count (Relative) 35-80% 39.44% 
Lymphocyte (Absolute) 800-4,800 /µl 5,630/ µl 
Lymphocyte (Relative) 18-44% 45.04 % 
Monocyte Count (Absolute) 200-900/µl 1,810/ µl 
Monocyte Count (Relative) 0-10% 14.48 % 
Eosinophil Count (Absolute) 0-800/µl 120 / µl 
Eosinophil Count (Relative) 0-3% 0.96% 
Basophil Count (Absolute) 0-100/µl 10/ µl 
Basophil Count (Relative) 0-1% 0.1% 
Platelet Count 150,000-350,000/µl 152,000/ µl 
MPV 7.4-10.4 fL 10.3 fL 
BMP 
Sodium 136-144 mEq/L 142 mEq/L 
Potassium 3.7-5.2 mEq/L 5.0 mEq/L 
Chloride 101-111 mmol/L 108 mmol/L 
CO2 20-29 mmol/L 24mmol/L 
BUN 7-20 mg/dL 14 mg/dL 
Creatinine 0.8-1.4 mg/dL 1.3 mg/dL 
Glucose 64-128 mg/dL 134 mg/dL 
Cholesterol < 200 mg/dL 210 mg/dL 
LDL 65-180 mg/dL 191 mg/dL 
HDL  35 mg/dL 
Triglycerides < 150 mg/dL 161 mg/dL 
A1c 4-5.6% 6.3% 
Liver Function Test 
ALT 0.-35 U/L 19 U/L 
ALP 36-92 U/L 59 U/L 
AST 0-35 U/L 24 U/L 
GT 0-30 U/L 23 U/L 
Total Bilirubin 0.3-1.2 U/L 0.8 U/L 
Conjugated Bilirubin 0-0.3 mg/dL 0.1 U/L 
Albumin 3.5-5.5 g/dL 4.2 g/dL 
 
1. Enzyme Immunoassay (EIA):  Negative for HIV antibodies.   
 
2. Tuberculin Skin Test (TST/PPD): 13 mm induration observed, positive test reading.  Patient has 
no history of taking the BCG vaccine, which means it could possibly be LTBI.  Further 
evaluation for active TB is required.  Needs a chest X-ray as soon as possible and eventually a 
sputum smear, culture, and sensitivity to further test for active TB, as well as check if the 











          (Physiopedia,2011) 
 
Arrows shows lung cavities in right upper lobe, while M shows the miliary pattern.  X-ray is 
indicative of active TB. 
 
Laboratory Findings (cont): 
 
3. Sputum Test for Acid-Fast Bacilli (AFB): Positive for Mycobacterium tuberculosis, 
clearly indicative of active TB that is potentially infective.  The patient is now isolated, 
and the ER doctor, who tested negative for TB 7 months ago was tested again as an 
immediate contact of an active TB case, is placed under observation; watching for any 
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signs of TB.   Additionally, family members and immediate contacts will be brought in 
for TB testing.  
 
4. QuantiFERON TB Gold In Tube (QFT) test : positive for TB antigens.  Test collected as 







Raul’s CBC showed lymphocytosis. Due to a DTaP immunization and a recent history of 
receiving the Tdap booster, pertussis is unlikely even though his symptoms (e.g. cough and 
congestion) could be consistent with pertussis.  In addition, hemoptysis is an unlikely symptom 
of pertussis.  HIV/AIDS shows similar symptoms such as night sweats, cough, and shortness of 
breath, and could be a major factor for immunosuppression causing LTBI progression to active 
TB.  But, the EIA showed no antibodies for HIV.   Moreover, lymphoma may show similar 
levels of lymphocytosis, and its metastasis to the lung could lead to symptoms like chronic 
cough, hemoptysis, and weight loss.  However, laboratory blood tests performed did not support 
such diagnosis.  A lack of an abnormal readings on the CXR makes lung cancer improbable.  
Additionally, cold and flu like symptoms are being considered, and the patient can have a 
severe case of influenza on top of his active TB.  However, it is highly unlikely that seasonal 
influenza would cause prolonged respiratory symptoms such as hemoptysis and decreased 
respiratory function.  However, during treatment, Raul should be observed as TB might just 




Diagnosis and Supporting Argument 
 
 Raul Meza is diagnosed with active pulmonary tuberculosis based on his present 
symptoms, the physical exam findings, and the positive PPD, CXR, sputum smear, and QFT 
gold test. 
 TB is not a very frequent infection as there are less than 100 newly diagnosed active TB 
cases in Nevada each year (Department of Health, 2015).  However, Raul’s symptoms are 
characteristic for active TB, especially his persistent cough, hemoptysis, weight loss, and night 
sweats.  Additionally, he is a diabetic Hispanic male who emigrated from a TB endemic area in 
Central America.  Also, his recent travels to his native country put him at an elevated risk for 
contracting TB.  The physical examination and lung auscultation illustrated that Raul had 
crackles in his upper lobes that are evident during inspiration. Moreover, these finding were 




The overall goals for Raul’s treatment aim to 1) cure his active TB, 2) prevent the 
transmission of M. tuberculosis to other individuals and 3) minimize the risk of drug resistance.  
Treatment will start with an initial phase of 8 weeks of antibiotic combination therapy, which 
include isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA).  One 
dosage of each (300mg INH, 600mg RIF, 800mg EMB, and 1,000mg PZA) will be administered 
daily for a total of 56 doses.  The continuation phase of treatment will be determined based on 
sputum culture results obtained during the completion of the initial treatment phase.  If the 
sputum culture is negative, there will be an additional 18 weeks of treatment with daily doses 
(126 doses) of INH, 300 mg, and RIF 600 mg.  However, if the sputum culture is positive, there 
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will 18 to 31 more weeks of treatment, depending on the AFB results after the first 8 weeks of 
the continuation phase, with daily doses of INH, 300 mg, and RIF, 600 mg.  If the AFB becomes 
negative after 8 weeks of the continuation phase of treatment, the 18 month plan will be 
followed. If the AFB culture continued to be positive, then the full 31 week plan (maximum plan 
with both initial and continuation being 9 months) will be administered (CDC, 2003).  
 Raul will be given patient-centered care which is supervised by the public health 
department, since a deviation from the plan could cause a threat of disease transmission into the 
community.  This strategy should include a strict adherence to the treatment plan, and the 
implementation of directly observed therapy (DOT).  Raul’s management plan will be 
individualized to ensure adherence to and completion of the drug regimen.  This may require 
direct involvement and support of the county social services and even the provision of incentives 
and enablers (CDC, 2003).  
Intact anti-tuberculosis medications should be administered together and split dosing 
avoided.  Mr. Meza will undergo routine monthly evaluations to identify any possible adverse 
effects of the medications and assess his adherence to the medication plan until the completion of 
the treatment (CDC, 2003). 
Since Raul is currently taking Vasotec, which has shown to have some drug interactions 
with INH and RIF.  He will be closely monitored to make sure that his hypertension is stabilized 
and under control.  If not, then he will be placed on another more appropriate anti-hypertensive 
medication (CDC, 2003).  Moreover, there is a small risk of exacerbating his peripheral 
neuropathy due to side effects of INH.  If peripheral neuropathy worsens, pyridoxine 
supplementation will be administered (CDC, 2013).  Also, any new medications should be 
discussed before being taken. 
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As active TB is infectious, his girlfriend and all his immediate contacts will be tested for 
TB.  They will also be instructed on the symptoms of TB and advised to seek out medical 




 Raul is very likely to be cured of TB if he adheres to the treatment regimen.  Because of 
evident cavitation observed in his CXR, he will mostly likely need to be on the full 9 month plan.  
However, AFB cultures will still be the determining factor for longevity of his continuation 
phase of treatment.  Once he is done with his treatment plan and his sputum cultures are 
negative, he will be clear of his M. tuberculosis but will have to continue to take his Metformin 
and anti-hypertensive medications.  With this medication plan, a relapse of TB symptoms is 
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